Therapeutic apheresis is a term that describes numerous different procedures that remove pathological substances from the body. They are used in cases when conservative treatment measures fail, and may be useful as an adjuvant method for treatment of different diseases which have a common feature pathogenic protein substance (paraproteins, antibodies...) or pathogenic substance attached to proteins (toxins), that has to be removed from the body. These substances could be removed by nonselective (plasmapheresis and therapeutic plasma exchange), semiselective (cascade apheresis) or selective methods (different adsorption techniques). The best results are achieved by selective methods, while they remove only pathogenic substances (useful substances remain in plasma), do not require replacement fluid, and have significantly less complications. Different methods of therapeutic apheresis achieved good results in treatment of age-related macular degeneration, sudden hearing-loss, dilatative cardiomyopathy, cardiovascular and cerebrovascular diseases, hepatic failure, inflammatory bowel diseases, and different neurologic conditions like Guillain-Barre syndrome, multiple sclerosis and myastenia gravis. They are useful in renal transplantation for cases with positive crossmatch or AB0 blood group incompatibility, as well as for treatment of acute humoral rejection. Methods of therapeutic apheresis are save and efficient when performed by experienced personel, trained to prevent, timely recognize and treate possible complications.
Download full-text PDF |
Source |
---|
J Investig Med High Impact Case Rep
January 2025
Marshall University, Huntington, WV, USA.
Thrombotic microangiopathy (TMA) is a severe condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage, often involving the kidneys. Complement-mediated hemolytic uremic syndrome (cHUS), a rare form of TMA, arises from dysregulated alternative complement pathway activation, frequently due to genetic mutations. We report the case of a 23-year-old male presenting with TMA secondary to a heterozygous mutation in the membrane cofactor protein (MCP/CD46) gene.
View Article and Find Full Text PDFLipids Health Dis
January 2025
Department of Gastroenterology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, 650051, China.
Background: This study examines the role and effectiveness of double filtration plasmapheresis (DFPP) in managing hyperlipidemiclipidemic acute pancreatitis (HLAP).
Methods: Comparative analysis was conducted between two groups: one treated with DFPP and one without. Comparative parameters included blood lipid levels, inflammatory factors, vital signs, disease severity scores, and complication rates.
Lancet Neurol
February 2025
Janssen Research & Development, a Johnson & Johnson Company, Titusville, NJ, USA.
Background: Given burdensome side-effects and long latency for efficacy with conventional agents, there is a continued need for generalised myasthenia gravis treatments that are safe and provide consistently sustained, long-term disease control. Nipocalimab, a neonatal Fc receptor blocker, was associated with dose-dependent reductions in total IgG and anti-acetylcholine receptor (AChR) antibodies and clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in patients with generalised myasthenia gravis in a phase 2 study. We aimed to assess the safety and efficacy of nipocalimab in a phase 3 study.
View Article and Find Full Text PDFBr J Nurs
January 2025
Deputy Corporate Lead Nurse, NHS Blood and Transplant, Lincoln.
Specialist nurses working in Therapeutic Apheresis Services (TAS) at NHS Blood and Transplant participate in an on-call rota. This means working above and beyond their rostered hours and can lead to them working 24 hours in one period. There is a noted risk of fatigue for people who work more than 13 hours in one stretch, and therefore it is important to understand how to recognise and manage the signs of fatigue.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Neurology (Nerve-Muscle Unit), Reference Center for Neuromuscular Diseases "AOC," ALS Reference Center, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France.
Rationale: Locked-in syndrome (and its variant, completely locked-in state) generally has a high mortality rate in the acute setting; however, when induced by conditions such as acute inflammatory polyradiculoneuropathy, it may well be curable such that an attempt at cure should be systematically sought by clinicians.
Patient Concerns: A 52-year-old man presented with acute tetraparesia and areflexia, initially diagnosed as Guillain-Barré syndrome. Despite appropriate treatment, his condition deteriorated, evolving into a completely locked-in state.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!